BioCentury
ARTICLE | Management Tracks

Mark Alles at the helm at Torl

Plus: new CSO at Nutcracker, and updates from Asieris, NewAmsterdam, Zura, Capstan and more

January 10, 2024 12:57 AM UTC

Cancer company Torl BioTherapeutics LLC named Mark Alles chairman and CEO, succeeding Dave Licata who will become CFO and continue as president and board member. Alles was chairman and CEO of Celgene Corp.

RNA therapies company Nutcracker Therapeutics Inc. promoted Samuel Deutsch to CSO from EVP of research and early development...